Peptides Explained

True-Sciences.com use code Pep20 for 20% off your first order What if some of the most important discoveries in regenerative medicine come not from replacing damaged cells, but from understanding how cells communicate? On this episode of Peptides Explained, John Garrett goes beyond the buzzwords surrounding stem cells and exosomes to explore the secretome—the complex collection of biological signals released by cells. We unpack growth factors, cytokines, extracellular vesicles, microRNAs, and the ways these signals may influence inflammation, tissue repair, remodeling, and cellular behavior. John explains why the cell is the factory and the secretome is its output—and why studying the output is not the same as proving that a manufactured preparation improves patient outcomes. You'll learn how extracellular vesicles differ from exosomes; why a molecule being present doesn't prove it reaches its target or creates a benefit; how cell sources and culture conditions affect what gets released; and what early human research does and does not show. John also shares a personal perspective: peptide medicines are an essential part of modern healthcare, but secretome science may be on the cusp of changing the way we think about healing and cellular communication. That's an informed prediction about the field's possibilities, not a claim that experimental secretome treatments are proven. This episode builds on John's earlier conversation with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy. This episode focuses on the biology and the evidence rather than reviewing a commercial product. Key topics: Cellular signaling; stem and stromal cells; paracrine effects; extracellular vesicles; exosomes; microRNA; inflammation; tissue repair; human clinical evidence; safety, manufacturing, and regulatory questions. Research links: https://doi.org/10.1002/jev2.12404 | https://pubmed.ncbi.nlm.nih.gov/39465400/ Peptides Explained App: https://app.peptidesexplained.info For educational purposes only. Experimental secretome-based interventions have not been established as safe or effective treatments for broad clinical uses. Speak with a qualified medical professional about treatment decisions. Any material financial relationships should be disclosed separately when applicable.

Weight loss is not the same thing as fat loss. A 2025 monkey study combining semaglutide with experimental myostatin and activin A antibodies raised the possibility of protecting lean mass while losing fat. Now COURAGE phase 2 data provide a human lean-mass preservation signal — alongside serious safety and tolerability concerns with the triple combination. John Garrett, RN, separates animal results, company-reported human data, body-composition measurements, and clinical outcomes. Trevogrumab and garetosmab are investigational monoclonal antibodies, not approved muscle-preserving peptides. Educational content only. Research links: https://doi.org/10.1038/s41467-025-59485-9 ; https://clinicaltrials.gov/study/NCT06299098 ; https://newsroom.regeneron.com/news-releases/news-release-details/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass

True-Sciences.com use code Pep20 for 20% off your first order Dr. Hany Demian joins John Garrett for a conversation about chronic pain, injury recovery, regenerative medicine, and where peptides may fit in patient care. Drawing on his clinical experience, Dr. Demian discusses how he approaches patients with different needs, why he avoids a "kitchen sink" approach, and why sleep, nutrition, exercise, and careful assessment still matter. They also talk about clinical judgment, patient safety, and situations where peptides may not be appropriate. The conversation includes clinical anecdotes and personal perspectives. These do not establish that a peptide is safe or effective. Evidence for compounds such as BPC-157 and TB-500 remains limited. This episode is for educational purposes and is not individualized medical advice.

BPC-157 is back in the compounding-policy conversation—but what does HHS's new notice actually change, and what does the human evidence show? In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty. For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is conditional and interim; it does not make BPC-157 FDA-approved, add it to the 503A Bulks List, or establish that it works. We also explain why the anti-doping rules are a separate question. This episode is for informational purposes only and is not medical advice. Research and policy details were checked October 30, 2026; verify current status before publication.

What if the future of regenerative medicine isn't just about stem cells—but the biological messages those cells send? In this episode of Peptides Explained, John Garrett sits down with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy, to explore the emerging science of secretomes, cellular communication, and regenerative medicine. Sanjiv shares his personal journey from pharmaceutical sciences and molecular diagnostics to becoming a patient facing significant health challenges. That experience sparked his interest in cell-free regenerative technologies and the biological signaling systems involved in tissue repair, inflammation, and aging. Together, John and Sanjiv explore: Secretome science: What secretomes are and how they differ from stem cells and exosomes. Cellular communication: How peptides, growth factors, cytokines, and extracellular vesicles influence biological signaling. Cell Factor: Sanjiv's explanation of the technology, manufacturing process, and potential applications. Mitochondrial health: The relationship between cellular energy, inflammation, and biological function. Healthspan vs. lifespan: Why extending healthy, functional years matters as much as extending life. Peptides and longevity: Sanjiv's personal experience with Cell Factor, SS-31, MOTS-c, and other interventions. The future of healthcare: The potential role of preventive medicine, personalized diagnostics, and emerging regenerative technologies. Sanjiv also discusses his own health improvements and his vision for expanding access to regenerative medicine through Regen Therapy and related ventures. The bigger question: Can scientists harness cellular signaling to improve human health, and what clinical evidence will be needed to demonstrate that these approaches are safe and effective? This is a conversation about scientific possibility, innovation, and taking a more active role in long-term health. Learn more: Cell Factor: https://cell.health/ RegenTherapy https://regentherapy.com Important disclaimer: This episode is for educational purposes only and does not constitute medical advice. Cell Factor and the experimental approaches discussed should not be considered proven treatments for kidney disease, diabetes, aging, or other medical conditions. Personal experiences are not controlled clinical evidence. Consult a qualified healthcare professional before making treatment decisions.